Choose Semaglutide If You have established cardiovascular disease (prior heart attack, stroke, stent, peripheral artery disease) You're over 50 with multiple cardiovascular risk factors (hypertension, high LDL, smoking history, family history) You've already lost most of the weight you want to lose and you're switching from short-term weight loss to long-term metabolic protection You want the longest-running real-world safety data on a GLP-1 Choose Tirzepatide If Your primary goal is maximum weight loss in the shortest timeframe You don't have established cardiovascular disease You've plateaued on semaglutide and need stronger appetite suppression You tolerate tirzepatide better (some people get less GI upset on dual agonism) What's Still Available After the FDA Crackdown 503A compounding pharmacies continue to prepare both peptides for documented medical need
Supplementing certain nutrients, such as vitamins B1, C, and E, as well as other antioxidants, may support your overall eye health
Research shows a 15% reduction in postprandial levels of GLP-1 in patients with type 2 diabetes
According to NICE Technology Appraisal 875 (TA875) , Wegovy is available on the NHS only through specialist weight management services for people who meet specific criteria, generally including a BMI of 35 kg/m or above with weight-related comorbidities (with lower thresholds for certain ethnic groups)
Appetite suppression typically becomes more noticeable as your dosage increases over time and your system adapts
